Oramed Pharmaceuticals (NASDAQ:ORMP) Issues Earnings Results

Oramed Pharmaceuticals (NASDAQ:ORMP) announced its earnings results on Thursday. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of $0.43 by ($0.59), Zacks reports.

Oramed Pharmaceuticals Price Performance

Shares of ORMP stock traded down $0.19 during trading on Friday, reaching $3.84. The company’s stock had a trading volume of 51,682 shares, compared to its average volume of 212,257. The company has a market capitalization of $159.91 million, a price-to-earnings ratio of 0.93 and a beta of 1.31. The stock’s 50-day moving average price is $4.38 and its 200 day moving average price is $4.05. Oramed Pharmaceuticals has a 1-year low of $2.25 and a 1-year high of $5.47.

Wall Street Analyst Weigh In

Several analysts have commented on ORMP shares. Wall Street Zen lowered shares of Oramed Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, November 7th. Weiss Ratings upgraded shares of Oramed Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Friday, October 23rd. One analyst has rated the stock with a Buy rating. According to MarketBeat.com, the stock has an average rating of “Buy”.

Insider Buying and Selling

In other Oramed Pharmaceuticals news, COO Joshua Hexter sold 30,000 shares of the business’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $4.51, for a total value of $135,300.00. Following the completion of the transaction, the chief operating officer owned 1,328,130 shares in the company, valued at $5,989,866.30. The trade was a 2.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Avraham Gabay sold 20,000 shares of Oramed Pharmaceuticals stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $4.51, for a total value of $90,200.00. Following the completion of the transaction, the chief financial officer owned 861,076 shares of the company’s stock, valued at approximately $3,883,452.76. This trade represents a 2.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.77% of the stock is owned by corporate insiders.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company developing oral drug-delivery technologies. Its platform is designed to protect protein-based medicines as they pass through the digestive system and support their absorption, with the aim of delivering medicines by mouth that have traditionally been given by injection. The company’s research has focused on oral treatments for metabolic conditions, including ORMD-0801, an oral insulin candidate, and an oral GLP-1 candidate. These products are investigational; Oramed does not market them as approved treatments.